Philogen SpA AI Stock Analysis
Want to see IT:PHIL full AI Analyst Report?
Philogen SpA (PHIL) AI Stock Analysis
Philogen SpA
(Milan:PHIL)
The score is supported primarily by strong recent financial performance (high margins, strong cash conversion, low leverage) and very attractive valuation (low P/E and solid yield). These positives are tempered by weak technical signals (below key moving averages with negative MACD and sub-50 RSI) and the company’s historically volatile growth and cash-flow momentum.
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 615.56M
- Dividend Yield
- 3.33%
- Average Volume (3M)
- 16.98K
- Price to Earnings (P/E)
- 3.8
- Beta (1Y)
- -0.11
- Revenue Growth
- 294.92%
- EPS Growth
- 390.98%
- Country
- Italy
- Employees
- 230
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma ski...
How the Company Makes Money
Philogen’s ability to generate revenue is primarily tied to advancing its proprietary drug candidates and monetizing its antibody-targeting technology through partnering. Key potential revenue streams include: (1) Licensing and collaboration income:...
Philogen SpA Financial Statement Overview
Summary
Strong inflection to very high profitability and cash generation in 2024–TTM with excellent cash conversion and low leverage. The main offset is volatility: revenue growth and free-cash-flow momentum have swung sharply and prior years were loss-making, reducing confidence in durability.
Income Statement
78PositiveBalance Sheet
86Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 315.27M | 314.32M | 74.00M | 23.13M | 23.71M | 2.50M |
| Gross Profit | 274.87M | 271.84M | 54.42M | 5.67M | 10.53M | -8.14M |
| EBITDA | 256.58M | 255.84M | 44.75M | -2.05M | -1.17M | -12.98M |
| Net Income | 224.98M | 229.68M | 45.29M | -6.16M | -5.38M | -15.72M |
Balance Sheet | ||||||
| Total Assets | 395.51M | 437.33M | 168.45M | 119.27M | 125.83M | 132.75M |
| Cash, Cash Equivalents and Short-Term Investments | 337.14M | 379.22M | 113.73M | 75.34M | 86.20M | 101.68M |
| Total Debt | 11.44M | 10.88M | 11.54M | 14.91M | 15.76M | 16.49M |
| Total Liabilities | 63.82M | 63.46M | 29.80M | 28.68M | 27.91M | 27.67M |
| Stockholders Equity | 331.69M | 373.86M | 138.66M | 90.59M | 97.92M | 105.09M |
Cash Flow | ||||||
| Free Cash Flow | 262.41M | 268.05M | 38.67M | -10.37M | -9.15M | -25.85M |
| Operating Cash Flow | 264.45M | 271.44M | 40.84M | -4.82M | -4.94M | -19.03M |
| Investing Cash Flow | -239.72M | -171.82M | -22.28M | 159.00K | 24.20M | -47.77M |
| Financing Cash Flow | -30.77M | -2.99M | -3.78M | -4.17M | -3.78M | 63.05M |
Philogen SpA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Negative. The current price of 21.05 is above the 20-day moving average (MA) of 21.05, below the 50-day MA of 21.96, and below the 200-day MA of 22.20, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 69.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHIL.
Philogen SpA Peers Comparison
Overall Rating
IT:DIA79Outperform
IT:PHIL77Outperform
IT:REC71Outperform
IT:ELN67Neutral
IT:FDA43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | EUR 4.55B | 26.27 | 13.91% | 1.54% | -3.13% | -22.16% | |
| 77Outperform | EUR 615.56M | 3.79 | 63.77% | 3.33% | 294.92% | 390.98% | |
| 71Outperform | EUR 10.87B | 20.65 | 24.82% | 2.55% | 8.27% | 30.25% | |
| 67Neutral | EUR 1.34B | 14.52 | 17.54% | 1.50% | 2.55% | 22.08% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 43Neutral | EUR 20.24M | -1.04 | -54.95% | ― | 13.94% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:PHIL | Philogen SpA | 21.05 | -1.43 | -6.35% | |
| IT:DIA | DiaSorin S.p.A. | 84.32 | 26.55 | 45.95% | |
| IT:ELN | El.En. S.p.A. | 16.70 | 5.60 | 50.42% | |
| IT:FDA | Fidia Spa | 0.02 | -0.18 | -91.96% | |
| IT:REC | Recordati Industria Chimica e Farmaceutica SPA | 52.65 | 1.76 | 3.46% | |
| IT:ARBS | Arterra Bioscience SpA | 3.01 | 0.10 | 3.44% |
Philogen SpA Corporate Events
Philogen Updates on Modest Progress in Ongoing Share Buyback Program
Philogen has provided an update on its ongoing share buyback program, reporting the repurchase of 3,766 treasury shares on Euronext Milan between 21 and 25 September 2026 for a total consideration of €84,420.13. These latest transactions raise the to...
Philogen expands treasury stake with continued share buybacks
Philogen S.p.A., a biotech group active in oncology and other severe diseases, leverages proprietary antibody and DNA-encoded library technologies to design tumor-targeting therapeutics, aiming to address conditions where current treatments remain in...
Philogen Adds to Treasury Stock with Latest Share Buyback Tranche
Philogen has reported fresh activity under its share buyback program, disclosing the repurchase of 3,626 shares on Euronext Milan between 31 August and 2 September 2026 at an average price of €22.9647, for a total outlay of €83,269.99. These latest p...
Philogen Reports Mediobanca Share Purchase on Italian Market
Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a Milan-based financial institution acting in an engagement capacity. The communication relates to Philogen’s ordinary shares, underscoring the company’s compli...
Mediobanca Reports Purchase of Philogen Shares on Italian Market
Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a major Italian financial institution acting under an unspecified engagement. The transaction, executed on July 22, 2026, on the EXM market segment, involved th...
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
Philogen S.p.A. has provided an update on its share buyback program, reporting the purchase of 230 treasury shares on Euronext Milan between 20 and 24 July 2026 at an average price of €22.80 per share, for a total outlay of €5,244.00. These latest tr...
Philogen resubmits strengthened EMA application for melanoma drug Nidlegy
Philogen has resubmitted an updated marketing authorization application to the European Medicines Agency for Nidlegy as a neoadjuvant therapy in adult patients with locally advanced, fully resectable melanoma. The dossier is now supported by longer m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026
